The person behind the Oncortaget is Mikhail Blagosklonny who is now at Roswell Park Cancer Institute and serves as a professor of Oncology there. In his career, he has come up with decisive ways and how to approach and treat cancer effectively. He also has ways of how to rejuvenate skin. He went to the First Pavlov State Medical University of St Petersburg and obtained his MD in Internal Medicine. He proceeded to get his Ph. D in Experimental Medicine and Cardiology in the same campus.
He began his career in New York an associate professor of medicine at New York Medical College. He has been in various medical research institutions, and his expertise in the scientific environments are now showing him as a scholar adding value to society. He majors in looking for anti-aging drugs, researching for more certain cancer therapies that will take care of the cancerous cells alone. He is a biogerontologist who explains the science behind aging. Visit Oncotarget’s profile page at Facebook.
He has come up with Rapamycin, medicine that can cure cancer and prevent aging. He also urges the old people to use the drug since it boosts their immunity. In his research, he focuses on Cellular and Molecular biology with clinical investigations. Mikhail concentrates on the following topics; cell cycle, apoptosis, signal transduction, ontogenesis, tumor suppressors, drug resistance, selective protection, mitosis and anticancer therapeutics.
As an author, he has written books on aging hyperfunction theory, cell cyclotherapy and the advantages of adding more technology on chemotherapeutic engineering. He has a careful approach on the cancer menace discovering that aging and cancer are very similar. E believes the solution to both, is using Rapamycin.
The articles that he has researched and written are more than 300. His journals and book chapters have been printed and published under his name. Moreover, he is an associate editor in PLOS ONE, American Journal of Pathology and the International Journal of Cancer. Mikhail has regularly been showing his willingness to help the masses in curing cancer. The journal is peer reviewed and is published by Impact Journals.
He is now the editor-in-chief of Oncotarget and Cell Cycle. He is a co-editor of cancer biology and therapy. Mikhail is on the editorial board of the Cell Death and Differentiation.